Influenza A H1N1 Monovalent Vaccine (Influenza A H1N1 Monovalent Vaccine) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 27, 2012

Influenza A H1N1 Monovalent Vaccine

Flu Vaccine: FDA Makes Sure There Is Enough »

How Flu Gets Around

Flu is spread through coughing or sneezing. You can also become infected by touching objects that are carrying the virus, such as telephones and door knobs, and then touching your mouth or nose.

Most healthy adults may be able to infect others one day before their own symptoms develop, and up to five days after becoming sick.

"Yearly immunization is the most effective way to prevent influenza and decrease influenza-related complications, which can include serious illness and death," says Jesse L. Goodman, M.D., M.P.H., Director of FDA's Center for Biologics Evaluation and Research.

Best Times to Immunize

It's best to be immunized as soon as the vaccine is available, usually in September. But getting vaccinated during winter months, when influenza season often peaks, is not too late and is also recommended.

Public health experts suggest ...

Read the Flu Vaccine: FDA Makes Sure There Is Enough article »

Influenza A H1N1 Monovalent Vaccine

The Common Cold Slideshow Pictures

Natural Cold and Flu Remedies Slideshow Pictures

Take the Cold & Flu Quiz

font size

Influenza A (H1N1) 2009
Monovalent Vaccine

DRUG DESCRIPTION

Influenza A (H1N1) 2009 Monovalent Vaccine, an inactivated influenza virus vaccine, for intramuscular use, is prepared from influenza viruses propagated in embryonated chicken eggs. The virus-containing allantoic fluid is harvested and inactivated with formaldehyde. Influenza virus is concentrated and purified in a linear sucrose density gradient solution using a continuous flow centrifuge. The virus is then chemically disrupted using a non-ionic surfactant, polyethylene glycol p-isooctylphenyl ether (Triton® X-100), producing a “split virus”. The split virus is further purified and then suspended in sodium phosphate-buffered isotonic sodium chloride solution.

Influenza A (H1N1) 2009 Monovalent Vaccine is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009 (H1N1) v-like virus per 0.5 mL dose. Gelatin 0.05% is added as a stabilizer. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 100 mcg), polyethylene glycol p-isooctylphenyl ether (not more than 0.02%), and sucrose (not more than 2.0%).

There is no thimerosal used in the manufacturing process of the single-dose presentations of Influenza A (H1N1) 2009 Monovalent Vaccine. The multi-dose presentation of Influenza A (H1N1) 2009 Monovalent Vaccine contains thimerosal, a mercury derivative, added as a preservative. Each 0.5 mL dose of the multidose presentation contains 25 mcg mercury.

Influenza A (H1N1) 2009 Monvalent Vaccine is a sterile clear to a slightly opalescent suspension.

Antibiotics are not used in the manufacture of Influenza A (H1N1) 2009 Monovalent Vaccine.

All presentations of Influenza A (H1N1) 2009 Monovalent Vaccine do not contain latex.

Last reviewed on RxList: 11/5/2009
This monograph has been modified to include the generic and brand name in many instances.